Please assess the completion status of the following clinical trial:

Trial Title: (Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~History of recurrent abdominal pain with cramping (APC) for at least three months.~Recorded at least two episodes of APC of at least moderate intensity (i.e., 5 or above on a 0-10 point scale) lasting one hour in the eDiary during the run-in period.~Exclusion Criteria:~Experiencing daily episode of APC during Run-in period Active gastrointestinal disease during the past 12 months including malignancy, inflammatory bowel disease, celiac disease or complete or partial bowel obstruction and who have undergone major gastrointestinal surgery with the past 12 months (patients with history of appendectomy, cholecystectomy, bilateral tubal ligation and c-section within past 12 months are allowed in the study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyoscine butylbromide (HBB) 20mg 1-5 tablets per episode (Type: ACTIVE_COMPARATOR): Patient to receive 1-5 tablets containing 20mg HBB per Abdominal pain associated with cramping (APC) episode
- Placebo (Type: PLACEBO_COMPARATOR): patient to receive a tablet identical to those containing HBB and take 1-5 tablets per episode

Based on this trial design, predict the completion outcome and termination type (if applicable).